Becton, Dickinson and Company
BDX (NYSE)
BDX currently offers a dividend yield of 2.53% and has delivered a 1-year return of 9.52, although it has seen a decline of 18.70% over the past five years. Analysts maintain a neutral outlook with a median 12-month price target of $168.01, suggesting potential upside, while ratings from firms like Barclays and Wells Fargo reinforce a cautious yet optimistic sentiment. Investors should consider the mixed historical performance alongside analyst recommendations when evaluating their position.
Pros:
- Stable dividend payments
- Strong position in healthcare market
Cons:
- Recent underperformance
- Market volatility risk
Becton, Dickinson and Company (BDX) may be suitable for investors seeking dividend income and a moderate 1-year return, but those concerned about long-term performance should weigh the significant decline over the past five years against analyst ratings that reflect a cautious optimism. Overall, potential investors should approach BDX with a balanced view of its recent performance and future prospects.